Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | NQO2 | P16083 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 2/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3969713 | 0.85 | LMNA (0.41) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| SCHEMBL23564604 | 0.80 | ELANE (0.45) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23717032 | 0.80 | KDM4E (0.57) | LMNAHPGDSMN1; SMN2KDM4EALDH1A1 | |
| SCHEMBL23717025 | 0.79 | MAOA (0.46) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| SCHEMBL23717024 | 0.79 | MAOA (0.43) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| SCHEMBL5321643 | 0.79 | ALOX15 (0.51) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| SCHEMBL6623084 | 0.79 | LMNA (0.50) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| SCHEMBL12526711 | 0.78 | ALOX15 (0.48) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| Hydrochloric Acid SCHEMBL6770342 | 0.77 | LMNA (0.49) | LMNAHPGDSMN1; SMN2ALOX15KDM4E | |
| SCHEMBL266444 | 0.77 | LMNA (0.64) | LMNAHPGDSMN1; SMN2ALOX15KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARM INC (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ENANTA PHARMACEUTICALS, INC. | 2023-04-06 | — | — | US | disclosed |
| CN-112174899-B | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2023-01-17 | — | — | CN | disclosed |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2022-08-23 | — | — | US | disclosed |
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| CN-112174899-A | Application of light-promoted Minisci C-H alkylation reaction in preparation of alkyl-substituted azacycle | 南开大学 | 2021-01-05 | — | — | CN | disclosed |
| US-9403839-B2 | Pyran-spirocyclic piperidine amides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-01-01 | — | — | US | disclosed |
| US-8778874-B2 | Glycopeptide antibiotic monomer derivatives | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2014-07-15 | — | — | US | disclosed |
| US-7595317-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | SHIONOGI & CO., LTD. (JP) | 2008-04-24 | — | — | US | disclosed |
| US-7294624-B2 | Osteoporosis; antiarthritic agents | BRISTOL MYERS SQUIBB COMPANY (US) | 2007-11-13 | — | — | US | disclosed |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | DUAN JINGWU | 2007-07-19 | — | — | US | disclosed |
| US-6936620-B2 | Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases | BRISTOL MYERS SQUIBB COMPANY (US) | 2005-08-30 | — | — | US | disclosed |
| WO-2003053941-A2 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003053940-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-$G(A) CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-03 | — | — | WO | disclosed |
| WO-2003040103-A1 | β-SULFONE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-α CONVERTING ENZYME (TACE) | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238188-A1 | HETEROCYCLIC COMPOUNDS AS ANTI-VIRAL AGENTS | VIP, ACE, FURIN | LMNA 2322/4885HPGD 36/4885SMN1; SMN2 713/4885 |
| US-20070167451-A1 | BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES | TNF, MMP9, MMP3 | LMNA 435/4885HPGD 478/4885SMN1; SMN2 3011/4885 |
| US-20150005304-A1 | Pyran-Spirocyclic Piperidine Amides as Modulators of Ion Channels | TRPV1, KCNJ2, KCNJ1 | LMNA 2134/4885HPGD 1119/4885SMN1; SMN2 1976/4885 |
| US-20080097078-A1 | Antibacterial activity against vancomycin-resistant bacteria | CSGALNACT1, MON2, NR2C2 | LMNA 4466/4885HPGD 3950/4885SMN1; SMN2 3927/4885 |
| US-11420976-B2 | Heterocyclic compounds as anti-viral agents | VIP, ACE, FURIN | LMNA 2322/4885HPGD 36/4885SMN1; SMN2 713/4885 |
| US-20230108803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | LMNA 2998/4885HPGD 41/4885SMN1; SMN2 1095/4885 |
| US-20230125803-A1 | ANTIVIRAL HETEROCYCLIC COMPOUNDS | ACE, HPRT1, ACE2 | LMNA 2998/4885HPGD 41/4885SMN1; SMN2 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.